Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Oct 24;4(12):1138-1146.
doi: 10.1002/ccr3.723. eCollection 2016 Dec.

All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature

Fabio Forghieri  1 , Sara Bigliardi  1 , Chiara Quadrelli  1 , Monica Morselli  1 , Leonardo Potenza  1 , Ambra Paolini  1 , Elisabetta Colaci  1 , Patrizia Barozzi  1 , Patrizia Zucchini  1 , Giovanni Riva  1 , Daniela Vallerini  1 , Ivana Lagreca  1 , Roberto Marasca  1 , Franco Narni  1 , Adriano Venditti  2 , Maria Paola Martelli  3 , Brunangelo Falini  3 , Francesco Lo Coco  4 , Sergio Amadori  2 , Mario Luppi  1
Affiliations
Case Reports

All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature

Fabio Forghieri et al. Clin Case Rep. .

Abstract

Based upon the clinical behavior of three patients, we suggest that the combination of low-dose Ara-C and all-trans retinoic acid may potentially be effective in some elderly patients, unfit for intensive chemotherapy, affected with NPM1-mutated acute myeloid leukemia without FLT3 mutations, warranting perspective clinical studies in these selected patients.

Keywords: All‐trans retinoic acid; NPM1‐mutated acute myeloid leukemia; elderly patients; low‐dose Ara‐C; unfitness for intensive chemotherapy.

PubMed Disclaimer

References

    1. Johnson, D. E. , and Redner R. L.. 2015. An ATRActive future for differentiation therapy in AML. Blood Rev. 29:263–268. - PMC - PubMed
    1. Burnett, A. K. , Milligan D., Prentice A. G., Goldstone A. H., McMullin M. F., Hills R. K., et al. 2007. A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109:1114–1124. - PubMed
    1. Schlenk, R. F. , Dohner K., Kneba M., Gotze K., Hartmann F., Del Valle F., et al. 2009. Gene mutations and response to treatment with all‐trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 94:54–60. - PMC - PubMed
    1. Burnett, A. K. , Hills R. K., Green C., Jenkinson S., Koo K., Patel Y., et al. 2010. The impact on outcome of the addition of all‐trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 115:948–956. - PubMed
    1. Nazha, A. , Bueso‐Ramos C., Estey E., Faderl S., O'Brien S., Fernandez M. H., et al. 2013. The addition of all‐trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemia. Front. Oncol. 3:218. - PMC - PubMed

Publication types

LinkOut - more resources